Health Care·Biotechnology·$2.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.56 | N/A | -78.52% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.56 | N/A | -78.52% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current financial performance. They highlighted ongoing challenges but did not offer specific future guidance.
Management did not provide specific guidance for future quarters.
The company acknowledged challenges in achieving profitability.
Sarepta Therapeutics reported a larger-than-expected loss per share, which contributed to an 8.4% decline in stock price. The lack of revenue information and guidance may raise concerns among investors about the company's short-term outlook. Overall, the market reacted negatively to the earnings report, reflecting uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
KONINKLIJKE PHILIPS ADR
Oct 22, 2018